Insights from 2023 ASH Annual Meeting
B

ASH 2023 Insights: "Prognostic Utility of MRD After Curative Intent Induction Therapy for DLBCL - A Prospective Real-World ctDNA Study"

By Insights from 2023 ASH Annual Meeting FEATURING Brian Sworder
By Insights from 2023 ASH Annual Meeting FEATURING Brian Sworder
112 views
December 18, 2023
0 Comments
Login to view comments. Click here to Login

Featured Video

15:14
Icahn School of Medicine at Mount Sinai

Safety Profile of Ruxolitinib in Patients With MF

Feat. D. Tremblay

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Related Content

AUTOPLAY
21:05
Louisville Hematology Highlights

Why Are Our Hematopoietic Stem Cells in the Bone Marrow?

Feat. R. Gale
10:04
Tara Graff

How to Incorporate Bispecific Antibodies Into Your NHL Practice: A P…

22:09
Scripps MD Anderson Cancer Center Clinical Hematology & Oncology 2024

New Updates in Frontline DLCBL

Feat. L. Nastoupil
62:02
UChicago Medicine

New Treatment Strategies in DLBCL

Feat. L. Sehn
17:21
Daniel Addison

Cardiovascular Considerations With (Contemporary) BTKi in the Treatm…

15:33
SOHO 2022 Tenth Annual Meeting

SOHO 2022: Has R-CHOP Really Been Replaced as Initial Therapy of DLB…

Feat. J. Friedberg
25:44
Tara Graff

DLBCL Updates From iCML 2023

06:09
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Outcomes of Pts With Richter's Transfo…

Feat. A. Kittai
17:11
SOHO 2023 Eleventh Annual Meeting

SOHO 2023: Incorporating Novel Agents in Frontline DLBCL

Feat. L. Sehn
35:28
UNC Lineberger Comprehensive Cancer Center

DLBCL Management: Updates for 2023

Feat. N. Grover
16:39
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

2024 Targeted Therapy Updates for Aggressive B-Cell Lymphomas

Feat. D. Landsburg
26:58
Total Health

Update on Cellular Therapy in Lymphoma

Feat. B. Randolph
17:51
Penn Medicine Cellicon Valley '23: The Future of Cell and Gene Therapies

Chronic GVHD: A Case-Based Discussion

Feat. L. Perry
35:24
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Aggressive B-Cell Lymphomas

Feat. G. Nowakowski
15:31
SOHO 2022 Tenth Annual Meeting

SOHO 2022: What's Next in Aggressive B-Cell Lymphoma?

Feat. L. Sehn
13:46
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Smart Stop Trial - Lenalidomide, Tafasitama…

Feat. J. Westin
33:36
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: Cell Therapy

Feat. M. de Lima
47:35
University of Colorado Division of Hematology

Overview of DLBCL: Diagnosis to Treatment

Feat. E. Fahey-Harrison
33:48
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: B-Cell Lymphoma

Feat. L. Nastoupil
02:53
PrecisCa

The POLARIX Trial: Polatuzumab With R-CHP in DLBCL

Feat. M. Kamdar